推荐产品
product name
EMT6/AR1, 96042327
生物源
mouse unknown/unspecified
增長模式
Adherent
染色體組型
Not specified
形態學
Epithelial-like
產品
Not specified
受體
Not specified
技術
cell culture | mammalian: suitable
相關疾病
cancer
運輸包裝
dry ice
儲存溫度
−196°C
細胞系來源
Mouse mammary, drug-resistant
細胞系描述
EMT6/AR1.0 was derived from the mouse mammary tumour cell line EMT6/P (Sigma Catalogue number. 96042344) by growth in increasing amounts of doxorubicin over a period of 8 weeks. The cell line showed a 40-fold greater resistance to doxorubicin, which is also known as adriamycin. The line was reported to express a classical multi-drug resistance (MDR) phenotype with hyperexpression of membrane P-glycoprotein and a spectrum of cross-resistance e.g. against vincristine and colchicine. Overexpression of CP22 (sorcin) and mdr 1a gene was reported. Cells were shown to have a reduced intracellular drug accumulation and exhibit a doubling time of 12-15 hours. It is recommended to culture the cells without drug after resuscitation until the first passage.
應用
Drug-resistance studies
培養基
MEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) +1.0 μg/ml doxorubicin + 10% Foetal Bovine Serum (FBS).
例行更新培養
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37ºC. Resuscitate in drug-free medium, add doxorubicin after first passage.
其他說明
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门